申请人:Acher Francine
公开号:US20090170813A1
公开(公告)日:2009-07-02
Hypophosphorous acid derivatives having Formula (I) wherein .M is a [C(R3,R4)]n1-C(E,COOR1,N(H,Z)) group, or an optionally substituted Ar—CH(COOR1,N(H,Z)) group, or an a, β, or a β, g-cyclic amino acid; .R
1
is H or R, R being an hydroxy or a carboxy protecting group; .Z is H or an amino protecting group R′, benzyl oxycarbonyl, benzyl or benzyl substituted; .E is H or a C1-C3 alkyl, aryl, an hydrophobic group; .R
2
is selected in the group comprising: D-CH(R
6
)—C—(R
7
,R
8
), (R
11
,R
12
)CH—C(R
9
,R
10
), D-CH(OH), D-[C(R
13
,R
14
)]
n3
—, C[(R
15
,R
16
,R
17
)]
n4
, D-CH
2
, (R
18
)CH═C(R
19
), D-(M
1
)
n6
—CO, Formula (II), PO(OH)
2
—CH
2
or (PO(OH)
2
—CH
2
), (COOH—CH
2
)—CH
2
, with -D=H, OH, OR, (CH
2
)
n2
OH, (CH
2
)
n1
OR, COOH, COOR, (CH
2
)
n2
COOH, (CH
2
)
n1
COOR, SR, S(OR), SO
2
R, NO
2
, heteroaryl, C
1
-C
3
alkyl, cycloalkyl, heterocycloalkyl, (CH
2
)
n2
-alkyl, (COOH,NH
2
)—(CH
2
)
u1
-cyclopropyl-(CH
2
)
u2
—, CO—NH-alkyl, Ar, (CH
2
)
n2
—Ar, CO—NH—Ar; —R
3
to R
19
being H, OH, OR, (CH
2
)
n2
OH, (CH
2
)
n1
OR, COOH, COOR, (CH
2
)
n2
COOH, (CH
2
)
n1
COOR, C
1
-C
3
alkyl, cycloalkyl, (CH
2
)n1-alkyl, aryl, (CH
2
)n1-aryl, halogen, CF
3
, SO
3
H, (CH
2
)
x
PO
3
H
2
, with x=0, 1 or 2, B(OH)
2
, Formula (III), NO
2
, SO
2
NH
2
, SO
2
NHR; SR, S(O)R, SO
2
R, benzyl; -M
1
is an alkylene or arylene group; -n1=1, 2 or 3, n2=1, 2 or 3, n3=0, 1, 2 or 3 and n4=1, 2 or 3, n5=1, 2 or 3, n6=0 or 1, u1 and u2, identical or different=0, 1 or 2, with the proviso that Formula (I) does not represent the racemic (3R,S) and the enantiomeric form (3R) of 3 amino,3-carboxy-propyl-2′-carboxy-ethylphosphinic acid; 3 amino,3-carboxy-propyl-4′carboxy,2′carboxy-butanoylphosphinic acid; 3 amino,3-carboxy-propyl-2′carboxy-butanoylphosphinic acid; 3 amino,3-carboxy-propyl-3′amino, 3′carboxy-propylylphosphinic acid; and 3 amino,3-carboxypropyl-7′amino-2′, 7′-dicarboxyheptylphosphinic acid, said hypophosphorous acid derivatives being diasteroisomers or enantiomers. Application as drugs.
含有Formula (I)的次磷酸衍生物,其中.M是[C(R3,R4)]n1-C(E,COOR1,N(H,Z))基团,或者是一个可选择取代的Ar—CH(COOR1,N(H,Z))基团,或者是α,β或αβ,γ-环氨基酸;.R1是H或R,R是一个羟基或羧基保护基团;.Z是H或氨基保护基团R′,苄氧羰基,苄基或苄基取代;.E是H或C1-C3烷基,芳基,疏水基团;.R2是从以下群体中选择的:D-CH(R6)—C—(R7,R8),(R11,R12)CH—C(R9,R10),D-CH(OH),D-[C(R13,R14)]n3—,C[(R15,R16,R17)]n4,D-CH2,(R18)CH═C(R19),D-(M1)n6—CO,Formula (II),PO(OH)2—CH2或(PO(OH)2—CH2),(COOH—CH2)—CH2,其中-D=H,OH,OR,(CH2)n2OH,(CH2)n1OR,COOH,COOR,(CH2)n2COOH,(CH2)n1COOR,SR,S(OR),SO2R,NO2,杂环芳基,C1-C3烷基,环烷基,杂环烷基,(CH2)n2-烷基,(COOH,NH2)—(CH2)u1-环丙基-(CH2)u2—,CO—NH-烷基,Ar,(CH2)n2—Ar,CO—NH—Ar;—R3到R19为H,OH,OR,(CH2)n2OH,(CH2)n1OR,COOH,COOR,(CH2)n2COOH,(CH2)n1COOR,C1-C3烷基,环烷基,(CH2)n1-烷基,芳基,(CH2)n1-芳基,卤素,CF3,SO3H,(CH2)xPO3H2,其中x=0,1或2,B(OH)2,Formula (III),NO2,SO2NH2,SO2NHR;SR,S(O)R,SO2R,苄基;-M1是一个烷基或芳基基团;-n1=1,2或3,n2=1,2或3,n3=0,1,2或3,n4=1,2或3,n5=1,2或3,n6=0或1,u1和u2,相同或不同=0,1或2,但Formula (I)不代表3-氨基,3-羧基-丙基-2′-羧基-乙磷酸的消旋体(3R,S)和对映体形式(3R);3-氨基,3-羧基-丙基-4′羧基,2′羧基-丁酰磷酸;3-氨基,3-羧基-丙基-2′羧基-丁酰磷酸;3-氨基,3-羧基-丙基-3′氨基,3′羧基-丙基磷酸;和3-氨基,3-羧基丙基-7′氨基-2′,7′-二羧基庚基磷酸,所述的次磷酸衍生物为二对映异构体或对映体。用作药物的应用。